Develops small-molecule drug candidates for rare genetic kidney diseases and, through a partner, rare skin diseases.
10-K for FY2025, filed Mar 17, 2026
Almirall is the customer for Eloxx’s license and service revenue and develops and commercializes ZKN-013 under an exclusive global rights agreement.
10-K for FY2025, filed Mar 17, 2026
10-Q for Q2 FY2026, filed Aug 11, 2026
−$4.5MView ↗
Partnered skin-disease program
The skin-disease candidate moved from Eloxx's own development pipeline to an exclusive global rights arrangement: Almirall is responsible for its development and commercialization, whereas the older report described Eloxx advancing it for rare skin diseases and FAP.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 17, 2026We are also advancing ZKN-013 as an oral agent for the treatment of RDEB/JEB and FAP patients with nonsense mutations. RDEB and JEB are…View ↗
We are also developing ZKN-013, an oral ribosome modulating agent (“RMA”) with structural similarity to azithromycin that induces PTC…View ↗
Stated development focus
The older report listed cystic fibrosis, FAP and oncology work alongside Alport and skin-disease programs; the latest identifies rare kidney diseases and partnered rare skin diseases as immediate priorities.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 17, 2026
Competes with Travere Therapeutics, River Renal, Bayer, Boehringer Ingelheim, Otsuka, AstraZeneca, Vertex Pharmaceuticals, Novartis, PYC Therapeutics, AbbVie, GSK, XORTX Therapeutics, Maze Therapeutics, Krystal Biotech, Abeona Therapeutics, Chiesi, Castle Creek, RHEACELL, and Inmune Bio
10-K for FY2025, filed Mar 17, 2026There are currently no FDA-approved therapies approved specifically for the treatment of AS. Disease management typically consists of ACEi…View ↗
Loading...